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The chicken anemia virus-derived Apoptin protein
induces tumor-specific apoptosis. Here, we show that
recombinant Apoptin protein spontaneously forms non-
covalent globular aggregates comprising 30 to 40 sub-
units in vitro. This multimerization is robust and virtu-
ally irreversible, and the globular aggregates are also
stable in cell extracts, suggesting that they remain in-
tact within the cell. Furthermore, studies of Apoptin
expressed in living cells confirm that Apoptin indeed
exists in large complexes in vivo. We map the structural
motifs responsible for multimerization in vitro and ag-
gregation in vivo to the N-terminal half of the protein.
Moreover, we show that covalently fixing the Apoptin
monomers within the recombinant protein multimer by
internal cross-linking does not affect the biological ac-
tivity of Apoptin, as these fixed aggregates exhibit sim-
ilar tumor-specific localization and apoptosis-inducing
properties as non-cross-linked Apoptin. Taken together,
our results imply that recombinant Apoptin protein is a
multimer when inducing apoptosis, and we propose that
this multimeric state is an essential feature of its ability
to do so. Finally, we determine that Apoptin adopts lit-
tle, if any, regular secondary structure within the aggre-
gates. This surprising result would classify Apoptin as
the first protein for which, rather than the formation of
a well defined tertiary and quaternary structure, semi-
random aggregation is sufficient for activity.
Apoptin is a protein from chicken anemia virus (CAV)1 that
induces apoptosis in transformed chicken cells (1). It has 121
amino acids and no known functional or sequence homologues.
When the gene encoding Apoptin is transduced into cultured
cells, the expressed Apoptin protein also induces apoptosis in a
wide range of transformed human cell lines (2). However, non-
transformed, normal human primary cell types are not killed.
Transformed and non-transformed cells differ markedly in the
subcellular localization of expressed Apoptin. In transformed
cells, Apoptin migrates to the nucleus, whereas in non-trans-
formed cells it is retained mainly within the cytoplasm. Al-
though nuclear localization of Apoptin appears to be essential
for apoptosis induction in transformed cells (3), the presence of
Apoptin in the nucleus alone is not sufficient to induce apo-
ptosis in normal cells.2 Two clusters of basic residues (Lys82-
Arg89, Arg111-Arg120) near the C terminus of Apoptin have been
implicated as a nuclear localization signal.
To correlate Apoptin’s biological activity with its structure
and biophysical properties, we studied several bacterially ex-
pressed, tagged recombinant Apoptin proteins. First, because
maltose-binding protein (MBP) fusion constructs can be effec-
tive in solubilizing aggregation-prone recombinant proteins, we
constructed N-terminally MBP-tagged Apoptin (4, 5). Second,
because histidine tagging can allow efficient refolding of pro-
tein immobilized on Ni2-chelating resin (6), we also con-
structed C-terminally hexahistidine-tagged Apoptin.
MBP-Apoptin fusion constructs were shown to be biologically
active and retain their distinct behavior in normal and tumor
cells upon microinjection.3 Here, we addressed Apoptin’s bio-
physical and structural properties and how these relate to its
biological function and found it to be biologically active as a
higher order multimer. However, no evidence was found for an
established regular structure.
MATERIALS AND METHODS
Cloning of Apoptin Expression Vectors (See Table I
for the Expressed Constructs)
pET-22bVp3, C-terminal Hexahistidine Fusion of Full-Length Apo-
ptin (Apoptin-H6)—The Apoptin open reading frame (ORF) was ampli-
fied by PCR from pET-11aVp3, which contains the Apoptin coding
sequence (nucleotides 427–868 in the CAV genome). The purified PCR
fragment was cloned at NdeI and NotI in pET-22b (Novagen), in which
a T7lac promoter, inducible with isopropyl--D-1-thiogalactoside
(IPTG), controls expression.
pET-22bVp3(1–69)H6, N-terminal 69 Residues of Apoptin with C-
terminal Hexahistidine Tag (Apoptin(1–69)-H6)—The N-terminal do-
main of Apoptin (ORF nucleotides 1–207) was amplified by PCR and
cloned in pET-22b at NdeI and AvaI.
pMalTBVp3, N-terminal Fusion of MBP and Full-length Apoptin
(MBP-Apoptin)—The Apoptin ORF was cloned at 5 BamHI and 3 SalI
in pMalTB, downstream of the Escherichia coli MalE ORF, which codes
for MBP. pMalTB is derived from pMal-c2 (New England Biolabs), and
the peptide linker between MBP and its fusion partner contains a
thrombin consensus site (-LVPR2GS-). Expression is controlled by an
IPTG-inducible Ptac promoter.
pMalTBVp3dC69H6 MBP Fusion of N-terminal 69 Residues of Apo-
ptin with C-terminal Hexahistidine Tag (MBP-Apoptin(1–69)-H6)—The
truncated Apoptin(1–69) ORF was amplified from pET-22bVp3(1–
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69)H6, including the downstream T7 terminator of pET-22b, and cloned
into pMalTB at BamHI and SalI.
pMalTBVp3dN66, MBP Fusion of C-terminal 56 Residues of Apoptin
(MBP-Apoptin(66–121))—The truncated Apoptin(66–121) ORF, includ-
ing the stop codon, was cloned in pMalTB at BamHI and SalI.
pcDNA3.1mychis()-MVp3—The full MBP-Apoptin ORF, including
the stop codon, was amplified by PCR from pMalTBVp3 and cloned at
NheI and KpnI in pcDNA3.1mychis() type B (Invitrogen). Expression
is controlled by a constitutive cytomegalovirus promoter.
pcDNA3.1mychis()-MVp3(80 –121)—pcDNA3.1mychis()-MVp3
was digested with BamHI and KpnI, removing the full Apoptin ORF.
Subsequently, the truncated Apoptin(80–121) ORF was amplified by
PCR and cloned into the linearized vector at BamHI and KpnI.
All clones were confirmed by automated fluorescent sequencing. Ta-
ble I summarizes the protein constructs we generated.
Bacterial Expression of Apoptin Constructs
Medium to large scale expression was performed in either of two
set-ups as follows: 1) 500 ml of expression medium in a 2-liter three-
baffled flask (Bellco Glass Inc.) (250 rpm, 37 °C); or 2) a 1.8-liter
bench-top fermentor (Biospec Products Inc.) (maximum agitation and
aeration, 37 °C). In both cases, a few drops of anti-foam A (Sigma) were
added directly prior to inoculation. For expression of MBP fusion pro-
teins, the LB medium was supplemented with 0.2% glucose to suppress
the expression of endogenous E. coli -amylases, which might interfere
with affinity purification of the fusion protein. E. coli BL21(DE3)
CaCl2-competent cells were transformed with one of the Apoptin con-
structs described above. A single transformant colony was grown over-
night in LB (0.2% glucose), supplemented with 200 g/ml carbenicil-
lin (Duchefa) and if necessary with 0.1 mM ZnSO4. After resuspending
the cells in fresh medium, a volume of expression culture (LB  0.2%
glucose, 100 g/ml carbenicillin, 0.1 mM ZnSO4) was inoculated 1 in
50. Upon reaching an A600 of 0.8 (2 to 3 h), expression was induced by
adding 1 mM IPTG. After 3 to 4 h (final A600  3 to 5), the cells were
harvested and lysed using a BeadBeater (Biospec Products Inc.). Lysis
buffers were as follows: 1) for MBP, MBP-Apoptin, MBP-Apoptin(1–
69)-H6, and MBP-Apoptin(66–121): 25 mM HEPES, pH 7.4, 500 mM
NaCl, 10% glycerol, 5 mM reduced glutathione (GSH) (Sigma), 2 mM
MgCl2, 1 protease inhibitor mixture (EDTA-free) (Roche Molecular
Biochemicals), DNase I (10 to 50 g/ml) (Roche Molecular Biochemi-
cals); 2) for Apoptin-H6: 1 PBS, 2 mM MgCl2, 1 mM phenylmethylsul-
fonyl fluoride (Invitrogen), DNase I; 3) Apoptin(1–69)H6, 50 mM KPO4,
pH 7.4, 2.5 mM imidazole (Fluka), 300 mM NaCl, 2 mM MgCl2, DNase I,
protease inhibitor mixture, 2.5 mM GSH. The glass bead/lysate slurry
was filtered (Whatmann 3MM) and centrifuged at 29,000  g for 15
min. Finally, lysates were fully cleared by filtering over a 0.22-m filter.
Purification of E. coli-expressed Protein
MBP-Apoptin and MBP-Apoptin(66–121)—The cleared lysate of a
1-liter expression culture was passed twice over an amylose column
(2.5 20 cm), equilibrated in 20 mM HEPES, pH 7.4, 500 mM NaCl, 10%
glycerol, 1 mM EDTA, or 0.1 mM ZnSO4, under gravity flow at 4 °C. The
column was washed with 5 column volumes (CV) of 20 mM HEPES, pH
7.4, 1 M NaCl, 1 mM EDTA, or 0.1 mM ZnSO4 followed by 5 CVs of 20 mM
HEPES, pH 7.4, 50 mM NaCl, 1 mM EDTA, or 0.1 mM ZnSO4. The
column was then eluted with 20 mM HEPES, pH 7.4, 50 mM NaCl, 1 mM
EDTA, or 0.1 mM ZnSO4, 10 mM maltose (Fluka). For all MBP fusion
proteins, phenylmethylsulfonyl fluoride (0.5 mM) was directly added to
the eluate to prevent degradation by traces of E. coli proteases. After
filtering, the eluate was loaded on an analytical cation exchange column
(UNO-S12) (Bio-Rad), equilibrated at 3 ml/min in 20 mM HEPES, pH
7.4, 50 mM NaCl, 1 mM EDTA, or 0.1 mM ZnSO4. After extensive
washing, the column was eluted with a 200-ml linear gradient (50–1000
mM NaCl, 5-ml fractions). Appropriate fractions were pooled and dia-
lyzed against PBS (CelluSep T1 membranes, molecular mass cut-off 3.5
kDa; Membrane Filtration Products Inc.). MBP-Apoptin and MBP-
Apoptin(66–121) were concentrated on a Biomax 5K or 10K Ultrafree
spin filter (Millipore) to 40 and 10 mg/ml, respectively. As a rule,
solutions of MBP-Apoptin fusion proteins were never subjected to
freeze/thawing and stored at 4 °C for up to one month. We noticed that
MBP-Apoptin, but not MBP alone, formed insoluble aggregates when
incubated at 1 mg/ml in PBS, 1 mM EDTA, 1% (32 mM) N-octylthio-
glucoside (OG) (Roche Molecular Biochemicals) for 1 h at 30 °C (data
not shown). Only a small amount of MBP-Apoptin remained in solution
under these conditions, as tested by Bradford protein assay (Bio-Rad).
We did not observe such an effect when OG was replaced by CHAPSO
(0.5%; Sigma) or Triton X-100 (1%; Roche Molecular Biochemicals).
Apoptin-H6—Starting with a 1.8-liter expression, the pellet after
lysis was resuspended in PBS, 0.5% Triton X-100 (Roche Molecular
Biochemicals) and stirred at room temperature for 1 h. The suspension
was then centrifuged at 29,000 g for 20 min, after which the inclusion
bodies were washed once with PBS. They were then resuspended in 50
mM HEPES, pH 7.4, 20 mM glycine, 2 mM EDTA, 20 mM DL-dithiothre-
itol, 8 M urea (molecular biology grade) (Invitrogen) and stirred over-
night at 4 °C. The cleared supernatant was then loaded on a UNO-S12
column, equilibrated at 3 ml/min in 20 mM KPO4, pH 7.4, 2.5 mM
imidazole, 2 mM GSH, 6 M urea. After washing, the column was eluted
with a 160-ml linear gradient (0–1 M NaCl, 5-ml fractions). Appropriate
fractions were pooled and stored at 80 °C if not used immediately
afterward. UNO-S12-cleaned Apoptin-H6 was mixed with a suspension
of 10 to 15 ml of Ni2-nitrilotriacetic acid (NTA)-agarose (Qiagen),
equilibrated in 20 mM KPO4, pH 7.4, 2.5 mM imidazole, 500 mM NaCl,
2 mM GSH, 6 M urea, and stirred at 4 °C for 2 h. The resin was packed
into a column, which was subsequently washed with 5 CVs of 20 mM
KPO4, pH 7.4, 20 mM imidazole, 500 mM NaCl, 2 mM GSH, 6 M guani-
dinium hydrochloride (Invitrogen). The denaturant was then removed,
in one step, by washing with 5 CVs of 20 mM KPO4, pH 6.5, 5 mM
imidazole, 400 mM NaCl, 2 mM GSH, 2 mM MgCl2. The protein was
eluted with the same buffer, supplemented with 500 mM imidazole. All
Ni2 traces were removed completely by adding 5 mM EDTA to the
eluted protein and dialyzing it against 20 mM KPO4, pH 6.5, 400 mM
NaCl, 2 mM MgCl2. Refolded Apoptin-H6 was concentrated on a Centri-
con YM3 filter (Amicon) to 10 mg/ml. Solutions of refolded Apoptin-H6
were never subjected to freeze/thawing and were stored for up to one
month at 4 °C.
MBP-Apoptin(1–69)-H6—The cleared lysate of a 1-liter expression
was applied to an amylose column, as described above. After washing,
the fusion protein was eluted in 50 mM KPO4, pH 7.4, 2.5 mM imidazole,
300 mM NaCl, 10 mM maltose. The eluate was filtered and loaded on a
Ni2-NTA-agarose column (1.5  5 cm), which was washed with 50 mM
KPO4, pH 7.4, 30 mM imidazole, 300 mM NaCl. The protein was eluted
with 50 mM KPO4, pH 7.4, 300 mM imidazole, 300 mM NaCl and
dialyzed against PBS, 0.5 mM EDTA.
MBP—Non-fused MBP was purified from IPTG-induced E. coli
BL21(DE3) transformed with pMalTB. After binding to amylose, the
column was washed with 20 mM Tris-HCl, pH 7.4, 1 mM EDTA. MBP
was then eluted with 20 mM Tris-HCl, pH 7.4, 1 mM EDTA, 10 mM
maltose and loaded on an analytical anion exchange column (UNO-Q1;
Bio-Rad). The column was eluted with a 20-ml linear gradient (0–1 M
NaCl, 1-ml fractions). MBP-containing fractions (1 to 5 mg/ml) were
dialyzed against PBS and then flash-frozen in liquid nitrogen and
stored at 20 °C.
Apoptin(1–69)-H6—The cleared lysate of a 1-liter culture was loaded
on a 5-ml Ni2-NTA-agarose (1.5  3 cm) column. The column was
washed with lysis buffer, supplemented with 100 mM imidazole, and
then eluted with 20 mM KPO4, pH 7.4, 500 mM imidazole, 500 mM NaCl.
After adding EDTA, the eluate was dialyzed to 20 mM KPO4, pH 6.5,
400 mM NaCl, 2 mM MgCl2. Apoptin(1–69)-H6 was concentrated on a
Centricon YM3 filter (Amicon) to 10 mg/ml.
TABLE I
Apoptin expression constructs
Construct Sequence Bacterial/Mammalian MW1/pI1
MBP MBP-(N)10-LVPRGSGG bacterial 42.6/5.1
MBP-Apoptin MBP-(N)10-LVPRGSGG-Apoptin(1–121) bacterial/mammalian 55.8/6.5
MBP-Apoptin(1–69)-H6 MBP-(N)10-LVPRGSGG-Apoptin(1–69)-LE-(H)6 bacterial 50.8/5.6
MBP-Apoptin(66–121) MBP-(N)10-LVPRGSGG-Apoptin(66–121) bacterial 49.1/6.1
MBP-Apoptin(80–121) MBP-(N)10-LVPRGSGG-Apoptin(80–121) mammalian 47.4/6.4
Apoptin-H6 Apoptin(1–121)-(A)3-LE-(H)6 bacterial 14.5/9.8
Apoptin(1–69)-H6 Apoptin(1–69)-LE-(H)6 bacterial 8.3/6.6
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Protein Concentration Determination
All protein concentrations were determined from A280. The extinction
coefficient of MBP-Apoptin and Apoptin-H6 at 280 nm (mg/ml/cm) was
1.0  0.1 and 0.10  0.01, respectively. The molecular mass of MBP-
Apoptin and Apoptin-H6 was taken as 55.8 and 14.5 kDa per monomer,
respectively.
Size Exclusion Chromatography
Samples were run as follows: 1) Sephacryl S100 HR (1.0  48 cm;
Amersham Biosciences), which was calibrated with blue dextran (2
MDa; Sigma) and Ponceau S (0.76 kDa; Sigma) at a flow rate of 11.5
cm/h in a sample load of 500 l; or 2) Superose 6 HR 10/30 (Amersham
Biosciences), which was calibrated with a size exclusion chromatogra-
phy calibration kit (Bio-Rad) (670, 158, 44, 17, and 1.35 kDa) at a flow
rate of 0.2 to 0.4 ml/min in a sample load of 100 l. For the second set
of conditions (Superose 6 HR), linear regression analysis of the elution
profile of the calibration run yielded log[molecular mass (kDa)] 
7.773  (0.365)[ml eluens].
Dynamic Light Scattering
All dynamic light scattering measurements were recorded on a Dy-
naPro-MS/X (Protein Solutions Inc.) at room temperature. Bovine se-
rum albumin was used as a control (0.5 mg/ml in PBS, 0.5 mM EDTA).
MBP-Apoptin was measured at 10 M (monomer concentration) in PBS,
0.5 mM EDTA, and refolded Apoptin-H6 at 35 M (monomers) in 20 mM
KPO4, pH 6.5, 400 mM NaCl, 2 mM MgCl2. Per experiment, between 20
and 40 measurements (10-s intervals) were collected. The hydrody-
namic radius of the particle (RH) was determined by averaging the
results of at least three separate experiments. Protein molecular mass
was estimated from the RH by the equation, MM (kDa)  [1.68 
RH]
2.34.
Circular Dichroism Spectroscopy
Far-UV circular dichroism spectra were recorded on a Jasco J-715
spectrometer. Spectrometer settings were as follows: wavelength range,
190–260 nm; cell width, 1 mm; scan speed, 50 nm/min; response time,
1.0 s; bandwidth, 1.0 nm; pitch, 0.1 nm. Spectra were averaged over
eight acquisitions. Throughout the measurements, the spectrometer
was flushed with O2-free N2 at 10 liters/min. Cell temperature was
maintained at 20 °C by a Jasco PTC-348WI Peltier element. MBP-
Apoptin was dialyzed to 10 mM KPO4, pH 6.5, 0.1 mM EDTA, or 0.1 mM
ZnSO4, and refolded Apoptin-H6 was dialyzed to 20 mM KPO4, pH 6.5,
1 mM MgSO4, or 0.1 mM ZnSO4. All samples and buffers were filtered
and degassed directly prior to measurement.
Fluorescence Measurements
Fluorescence emission and excitation spectra were recorded on a
PerkinElmer Life Sciences LS-50B. Fluorimeter settings were as fol-
lows: slit width, 6 nm; scan speed, 120 nm/min; excitation wavelength,
280 nm. Final spectra were obtained by averaging three separate spec-
tra. Background emission and excitation spectra were recorded of the
respective filtered buffers. The concentration of refolded Apoptin-H6
was 55 M (monomer concentration) in refolding buffer (20 mM KPO4,
pH 6.5, 400 mM NaCl, 2 mM MgCl2). The concentration of free tyrosine
(L-Tyr) was 7.5 M in Apoptin-H6 dialysis buffer, pH 6.5, and 500 M in
50 mM Na3PO4, pH 12, 1 mM EDTA.
Scanning Force and Electron Microscopic Analysis
Biotin Labeling—Fresh MBP-Apoptin (20 mg/ml, 0.1 M NaHCO3, pH
8.3) was incubated with 5 mM sulfo-NHS-LC-biotin (Molecular Probes,
Inc.) at room temperature for 3 h. The reaction was terminated by
adding 10 mM ethanolamine. To remove unincorporated label, the la-
beled protein was passed over a PD-10 desalting column (Amersham
Biosciences), equilibrated in 20 mM HEPES, pH 7.4, 0.1 mM EDTA.
Electron Microscopy—Both labeled and unlabeled MBP-Apoptin (30
mg/ml, in 20 mM HEPES, pH 7.4, 0.1 mM EDTA) were filtered over
0.22-m spinfilters (Ultrafree-MC; Millipore) and adsorbed to a carbon-
coated polioform layer grid. Both samples were incubated with concen-
trated streptavidin-gold conjugate (gold particle diameter, 5 nm)
(Kirkegaard & Perry Laboratories Inc.) and stained with 3% uranyl
acetate. Electron microscopy was performed on a Philips TEM 410
transmission electron microscope.
Scanning Force Microscopy—90 ng of purified MBP-Apoptin (in 10 l
of 5 mM HEPES, pH 7.9, 3 mM KCl, 5.5 mM MgCl2) was incubated at
37 °C for 15 min and then deposited on a disc of freshly cleaved mica
(Ted Pella Inc.). After 20 s, the mica was gently rinsed with high
pressure liquid chromatography water. Excess water was removed, and
the disc was dried with a steady flow of 0.22 m of filtered air. Images
were acquired on a Nanoscope IIIa (Digital Instruments Inc.), operating
in tapping mode in air with a type E scanner. Silicon tips were obtained
from Digital Instruments.
SDS-PAGE and Western Blotting
SDS-PAGE—Protein samples were run on 7.5–15% SDS-PAGE gels,
either under reducing or non-reducing conditions, i.e. with or without
-mercaptoethanol in the sample buffer. 1 SDS-PAGE sample buffer
contained 20 mM Tris-HCl, pH 6.8, 0.01% bromphenol blue, 1% SDS,
10% glycerol, 1% -mercaptoethanol. Gels were stained with Coomassie
Brilliant Blue (Bio-Rad).
Western Blotting and Dot Blotting—Samples were run on SDS-PAGE
and blotted onto Immunoblot polyvinylidene difluoride membranes
(Bio-Rad) or dot blotted directly onto polyvinylidene difluoride after
denaturation in 1 SDS-PAGE sample buffer (95 °C for 5 min). Blots
were probed with the anti-Apoptin monoclonal antibody 111.3 (epitope,
residues 18 to 23) (2) or with the polyclonal anti-Apoptin antibody
VP3-C, which has an epitope range comprising residues 79 to 90 (9).
Blots were subsequently incubated with an appropriate horseradish
peroxidase-conjugated secondary antibody and developed by enhanced
chemiluminescence.
Fluorescent Zinc Assay
Calibration Curve—A concentration range of ZnSO4 (1 to 20 M)
(Fluka) was prepared in assay buffer (50 mM HEPES, pH 7.4, 0.2%
SDS), to which 200 nM FluoZin-1 (Molecular Probes) was added to from
a 2 mM stock solution in water. Fluorescence spectra were recorded
after 15 min of equilibration at room temperature. Spectra were ad-
justed for background fluorescence, which was determined from a sam-
ple of FluoZin-1, to which 5 mM EDTA had been added. Fluorimeter
settings were as follows: slit width, 4 nm; scan speed, 120 nm/min;
excitation wavelength, 495 nm.
Sample Preparation—Protein samples were as follows. 1) MBP-Apo-
ptin was expressed in the presence of 0.1 mM ZnSO4 and purified
without using EDTA. 2) MBP-Apoptin, expressed without additional
Zn2 and treated with EDTA, was incubated with a 10-fold molar excess
of ZnSO4 overnight at 4 °C (in PBS). Both samples were desalted on a
PD-10 column, equilibrated in 50 mM HEPES, pH 7.4, and then dena-
tured in 0.5% SDS (95 °C for 5 min). After cooling to room temperature,
the samples were diluted in assay buffer to 10 M final protein concen-
tration (monomers) and 0.2% final SDS concentration. Fluorescence
spectra were recorded after addition of FluoZin-1.
Fluorescent Labeling and Chemical Cross-linking
Fluorescent Labeling—The number of solvent-exposed Cys residues
per MBP-Apoptin monomer was determined using 5,5-dithiobis(2-ni-
trobenzoic acid) (Sigma) (10). Fresh MBP-Apoptin (5 mg/ml, PBS) was
incubated with 2 mM of fluorescein-5-maleimide (Molecular Probes),
diluted from a freshly prepared 20 mM stock solution in 50 mM Na3PO4,
pH 12, and incubated overnight at 4 °C in the dark. The labeling
reaction was stopped by adding 10 mM -mercaptoethanol, after which
unincorporated label was removed by passing the protein over a PD-10
column (Amersham Biosciences), equilibrated in PBS. The level of label
incorporation was determined from the equation, [A/EC]  [MM/C],
where A is the absorbance of the label, C is the concentration of labeled
protein (in mg/ml), EC is the molar extinction coefficient of the label
(cm/M), and MM is the molecular mass of the protein (in Da).
Cross-linking—Following labeling with fluorescein-5-maleimide, the
protein (3 mg/ml) was incubated with 0.05% glutaraldehyde, diluted
from a 8% stock solution in water (grade I; Sigma), for 3 min at 30 °C (in
the dark). The reaction was stopped by adding 50 mM -alanine (Fluka).
After 20 min, the protein was passed over a PD-10 column, equilibrated
in PBS.
Incubation of Recombinant MBP-Apoptin in Saos-2 and
VH10 Lysates in Low Detergent Buffer
Saos-2 cells, which are human tumor cells derived from osteosar-
coma, and VH10 cells, which are normal human fibroblasts, were grown
to around 50% confluency. The cells were washed with cold PBS and
harvested in ice-cold 25 mM HEPES, pH 7.4, 150 mM KCl, 2 mM MgCl2,
5 mM dithiothreitol, 2.5 mM benzamidine hydrochloride (Sigma), 0.25%
CHAPSO (Sigma). The suspensions were sonicated on ice, after which
insoluble material was removed by centrifugation at 29,000  g for 20
min. After determining the respective protein concentrations, MBP-
Apoptin was added to 5% (w/w), which was estimated to be the average
ratio of MBP-Apoptin to cytoplasmic protein in microinjected cells (7, 8).
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Samples were incubated for 30 min at 30 °C, in the presence of 1 mM
ATP and 20 mM MgCl2, and for 2 and 24 h at 4 °C, without additives.
Following incubation, samples were fractionated on Superose 6 HR
10/30. Prior to fractionation, any precipitated material was pelleted by
centrifugation at 29,000  g for 20 min, after which the pellets were
washed with lysis buffer. All pellets and fractions were dot blotted,
using 10 l per sample, as described above. Dot blots were probed with
mAb 111.3.
Microinjection
Saos-2 and VH10 cells were cultured in Dulbecco’s modified Eagle’s
medium containing 10% fetal calf serum, penicillin and streptomycin
(Invitrogen). Cells were seeded in 35-mm tissue glass-bottomed culture
dishes and grown to 30 to 40% confluency prior to microinjection.
During microinjection, cells were incubated in RPMI 1640 medium (25
mM HEPES, pH 7.2, 5% fetal calf serum, penicillin, and streptomycin)
at 37 °C. Cells were returned to Dulbecco’s modified Eagle’s medium
directly after microinjection. Microinjection was performed with 0.5-m
microneedles (sterile femtotips II; Eppendorf) under an inverted micro-
scope (Axiovert 135 TV; Zeiss), equipped with a programmable micro-
injector (IM 300; Narishige Co.) and a joystick hydraulic micromanip-
ulator (MMO-202; Narishige Co.). Fluorescein-labeled, cross-linked
MBP-Apoptin (3 mg/ml, in PBS) was combined with lysine-fixable rho-
damine-dextran (Molecular Probes) to mark injected cells. Directly
prior to injection, protein samples were filtered over 0.22 m or centri-
fuged at 15,000  g for 15 min. An injection pressure of 0.5 to 1.0
pounds/square inch, and an injection time of 0.2 to 0.5 s was used. For
analysis of apoptotic activity, 100 cells were injected per dish.
Transient Transfection and Protein Extraction
Saos-2 cells were seeded in 9-cm plates at 20% confluency and trans-
fected with 7 g of DNA using FuGENE 6.0 (Roche Molecular Biochemi-
cals) according to the manufacturer’s protocol, pcDNA3.1mychis()-
MVp3, pcDNA3.1mychis()-MVp3 (80–121) (3:1 l/g FuGENE:DNA
ratio), or mock-transfected. For analysis of protein solubility, cells were
trypsinized and washed with 1 PBS 2 days after transfection. Cells
were pooled from two dishes per construct and resuspended in 200 l of
20 mM Tris-HCl, pH 7.5, 250 mM NaCl, 5 mM EDTA, 0.1% Triton X-100,
20 mM -glycerophosphate, 5 mM NaF, 5 mM GSH, 2 protease inhib-
itor mixture (Roche Molecular Biochemicals), and left on ice for 30 min.
Cell debris and the bulk of the insoluble protein fraction were pelleted
by centrifugation at 10,000  g for 20 min at 4 °C. After separating
supernatant (S10) and pellet (P10), we centrifuged the supernatant at
30,000  g for 20 min, yielding S30 and P30. Protein samples were
Western blotted, as described above, and blots were stained with
VP3-C.
(Immuno)fluorescence Microscopy
Microinjection—2 and 24 h after injection, cells were fixed sequen-
tially with PBS, 1% freshly prepared formaldehyde (10 min) and then
100% cold MeOH (5 min) and 80% cold acetone (2 min). Fluorescein-
labeled, cross-linked MBP-Apoptin was detected by direct fluorescence.
The apoptotic condition of individual cells was deduced from their
nuclear morphology after staining with 2,4-diamidino-2-phenylindole
(DAPI).
Transient Transfection—In a parallel experiment, Saos-2 cells were
grown on coverslips in 9-cm plates and transfected as described above,
fixed using fresh 1:1 methanol:acetone for 5 min, and stained with a
mouse monoclonal antibody that recognized MBP (clone R29.6; Abcam).
An appropriate fluorescein isothiocyanate-labeled secondary antibody
was added, and the cells were mounted in DAPI/DABCO(1,4-diaza-
bicyclo[2.2.2]octane)/glycerol. Again, apoptotic cells were scored on the
basis of their nuclear morphology. Detection of MBP-Apoptin with
VP3-C produced comparable results.
RESULTS
Recombinant Apoptin Forms Non-covalent
Multimeric Complexes
MBP-Apoptin—In E. coli, soluble MBP-Apoptin was ex-
pressed with a yield of up to 100 mg per liter of culture. After
affinity chromatography on amylose resin and cation exchange
chromatography, MBP-Apoptin migrated as a stable multim-
FIG. 1. Recombinant MBP-Apoptin and Apoptin-H6 form non-covalent multimeric complexes. Size exclusion chromatography of
MBP-Apoptin and refolded Apoptin-H6 on Superose 6 HR 10/30 are shown. A, calibration with gel filtration standards in PBS indicating the
resolving power of the column was as follows: thyroglobulin, 670 kDa; -globulin, 158 kDa; ovalbumin, 44 kDa; myoglobin, 17 kDa; vitamin B12,
1.4 kDa. B, MBP-Apoptin, 10 mg/ml in 2 PBS, 0.5% CHAPSO. The low intensity peak at about 17 ml elution volume was caused by a trace amount
of non-fused MBP. C, refolded Apoptin-H6, 7 mg/ml in 20 mM KPO4, pH 6.5, 400 mM NaCl, 2 mM MgCl2, 5 mM Cys-HCl. D, purified
MBP-Apoptin(1–69)-H6, 15 mg/ml, in PBS. During purification, proteolytic cleavage occurred at the thrombin cleavage sites in the peptide linker
between MBP and Apoptin(1–69)-H6. The peak at 12.5 ml elution volume is the intact fusion protein, the peak at 17.5 ml is MBP alone. E, purified
MBP-Apoptin(66–121), 5 mg/ml in PBS.
Multimerization of Recombinant Apoptin Protein 9045
 at W
A
LA
EU
S LIBRA
RY
 on M
ay 1, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
eric complex, with a molecular mass of 2.5  0.3 MDa, on an
analytical size exclusion chromatography column (Superose 6
HR 10/30) (Fig. 1, A and B). The molecular mass of the MBP-
Apoptin monomer is 56 kDa; see Table I. Analysis of purified
MBP-Apoptin by scanning force microscopy and electron mi-
croscopy showed a uniform population of globular particles
with a radius of 40 nm (Fig. 2, A and B). Dynamic light
scattering (DLS1) confirmed that the MBP-Apoptin complex is
present as a single solute species with an average RH of 17.9 
2.0 nm, which corresponds to a diameter of 36  4.0 nm and an
estimated molecular mass of 2.9  0.6 MDa. The variation in
the average RH of the MBP-Apoptin particle among four sepa-
rate protein batches remained within experimental error (16 to
20 nm). The multimerization of MBP-Apoptin was independent
of the protein concentration (0.5 to 25 mg/ml), ionic strength
(up to 0.4 M NaCl), and the presence of detergent (0.5%
CHAPSO or 1% Triton X-100). Despite the high stability of the
complex, there were no covalent bonds between individual
MBP-Apoptin monomers, because only monomers could be ob-
served upon boiling in SDS followed by SDS-PAGE under non-
reducing conditions (Fig. 3A). We noticed that MBP-Apoptin
precipitated nearly completely when incubated in 1% OG (in
PBS), a non-denaturing detergent, for 1 h at 30 °C (data not
shown). Because MBP alone did not precipitate under the same
conditions, it appeared that N-octylthioglucoside selectively
destabilized the Apoptin multimer. This result suggests that
hydrophobic interactions play an essential role in the formation
of Apoptin protein multimers.
In addition to the full-length MBP-Apoptin fusion protein,
which migrated as a 58.5-kDa species on SDS-PAGE, three
less-abundant expression products of 56.7, 53.3, and 50.1 kDa
consistently co-purified with the MBP-Apoptin multimer. All
three could be detected with the anti-Apoptin mAb 111.3 (Fig.
3B). These products could not be removed under native condi-
tions, demonstrating that the degradation products were still
incorporated into the MBP-Apoptin complex. The linker pep-
tide that connects the MBP and Apoptin moieties contains a
thrombin cleavage site. When the fusion protein was digested
with thrombin, cleaved-off MBP was released from the com-
plex, whereas the Apoptin moieties remained part of it, indi-
cating that the multimerization behavior of MBP-Apoptin de-
pended entirely on the Apoptin moiety (data not shown).
Apoptin-H6—In E. coli, inclusion bodies of Apoptin-H6 were
expressed with a yield of up to 40 mg per liter of culture.
Manipulating growth or lysis conditions did not increase the
solubility of Apoptin-H6. After solubilization in 8 M urea, Apo-
ptin-H6 was purified to 90% homogeneity by cation exchange
chromatography under denaturing conditions (6 M urea). It
could be refolded with a net efficiency of 50% in a single step
while bound to Ni2-NTA-agarose. On Superose 6 HR 10/30,
refolded Apoptin-H6 migrated as a single species with a molec-
ular mass of 400  50 kDa, independent of protein concentra-
tion (1 to 7 mg/ml) (Fig. 1C). The molecular mass of the Apop-
tin-H6 monomer is 14.5 kDa; see Table I. The two additional
peaks of 30 and 10 kDa in the Superose 6 elution profile were
unlikely to contain Apoptin as they were not recognized by the
Apoptin-specific antibody mAb 111.3. DLS confirmed the par-
ticle size, indicating a single solute species with an RH of 8.5 
1.0 nm, corresponding to a molecular mass of 500  100 kDa.
The variation in complex size among three separate protein
batches remained within experimental error (8 to 10 nm).
Like the MBP-Apoptin complex, the Apoptin-H6 complex was
non-covalent, as shown by non-reducing SDS-PAGE (Fig. 3C).
A number of additional species migrating with apparent mo-
lecular masses of 8, 34, and 48 kDa could be detected by mAb
111.3 (Fig. 3D). The smallest mAb 111.3-reactive species (8
kDa) corresponded to an N-terminal fragment lacking the C-
terminal hexahistidine tag. As in the MBP-Apoptin complexes,
fragments truncated at the C terminus remained associated
and co-purified.
Mapping the Regions Required for Multimerization: N- and
C-terminal Domains of Apoptin—To evaluate the ability of
fragments of Apoptin to form multimers, Apoptin’s N-terminal
69 residues and C-terminal 56 residues (66–121) were cloned
separately as MBP fusion proteins. The MBP-Apoptin(1–69)
fusion also contained a C-terminal hexahistidine tag to facili-
tate further purification. In E. coli, soluble MBP-Apoptin(1–
69)-H6 was expressed with yields of up to 100 mg per liter of
culture. It displayed the same elution profile on size exclusion
chromatography as did full-length MBP-Apoptin(1–121), indi-
cating that the complex is about 2.5 MDa in size (Fig. 1D). As
with the full-length MBP-Apoptin complex, Apoptin(1–69)-H6
with its MBP moiety cleaved off co-eluted with the intact fusion
protein (data not shown).
In E. coli, soluble Apoptin(1–69)-H6 was expressed with a
yield of up to 2 mg per liter of culture. After Ni2-NTA-agarose
purification, the homogeneity of Apoptin(1–69)-H6 was 80%.
When the Ni2-NTA-agarose eluate was fractionated on a
Sephacryl S100 HR gel filtration column, the Apoptin(1–
69)-H6 could only be recovered from the void volume. This
FIG. 2. Analysis of MBP-Apoptin multimers by scanning force
microscopy and electron microscopy. The Apoptin multimeric com-
plex is globular and has a diameter of about 40 nm. A, scanning force
microscopy analysis was as follows: MBP-Apoptin (in 5 mM HEPES, pH
7.9, 5.5 mM MgCl2, 3 mM KCl) was deposited onto freshly cleaved mica
and then air-dried. The surface area is 3  3 m. Height is indicated in
grayscale, and the bar is from 0.0 (black) to 1.5 nm (gray). B, electron
microscopy analysis was as follows: biotin-labeled MBP-Apoptin (30
mg/ml) was adsorbed onto a carbon-coated polioform layer grid and
incubated with a streptavidin-gold conjugate (diameter gold particles
5 nm). Between 5 and 10% of globules showed gold binding, whereas
a-selective binding was less than 0.1%. Negative staining was done with
3% uranyl acetate. Bar represents 100 nm.
FIG. 3. Apoptin degradation products co-purify with full-
length recombinant protein in the multimeric complex. SDS-
PAGE and Western blot analysis of purified MBP-Apoptin and refolded
Apoptin-H6 are shown. MBP-Apoptin was run on 10% SDS-PAGE, and
refolded Apoptin-H6 was run on 13.5% SDS-PAGE. Western blots were
probed with the anti-Apoptin monoclonal antibody mAb 111.3. A, puri-
fied MBP-Apoptin. 1, non-reduced; 2, reduced. B, Western blot of MBP-
Apoptin. C, purified, refolded Apoptin-H6. 1, reduced; 2, non-reduced. D,
Western blot of refolded Apoptin-H6.
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finding indicated that Apoptin(1–69)-H6 formed a complex of at
least 100 kDa in size under non-denaturing conditions (data
not shown). The molecular mass of the Apoptin(1–69)-H6 is 8.3
kDa; see Table I.
MBP-Apoptin(66–121) was expressed in soluble form to 50
mg per liter of culture. Purified MBP-Apoptin(66–121) mi-
grated at50 kDa on SDS-PAGE. In contrast to the full-length
fusion protein, MBP-Apoptin(66–121) consisted exclusively of
two species of 200 and 60 kDa, which may correspond to an
equilibrium between a monomer and a di- or trimer (Fig. 1E).
The molecular mass of MBP-Apoptin(66–121) is 49 kDa; see
Table I. DLS analysis indicated that there was only one solute
species present, with an RH of 4.6  0.8 nm, which corresponds
to an average molecular mass of 120  50 kDa. Regardless of
the precise nature of the two species, this result shows that the
C-terminal domain of Apoptin on its own is unable to form the
type of higher order multimers such as MBP-Apoptin(1–121)
does. Taken together, these results demonstrate that the N-
terminal 69 residues of Apoptin contain sufficient structural
elements to account for its multimerization behavior.
Apoptin Has Little if Any Ordered Structure
Next, we examined whether recombinant Apoptin protein
harbors any secondary or tertiary structure, using circular
dichroism (CD) and fluorescence spectroscopy.
CD Spectroscopy—The far-UV CD spectrum of refolded Ap-
optin-H6 (Fig. 4A) showed a very small mean residue ellipticity
([]MRE) at 222 nm, indicating that the protein was nearly
devoid of -helical structure (11). Refolded Apoptin-H6 also
contained little -sheet structure, which could be deduced from
a small positive []195 and a small negative []216 (11). The k2d
program for protein secondary structure prediction from CD
spectra (12) could not assign any -helical or -sheet structure.
Although refolded Apoptin-H6 had little if any secondary struc-
ture, it did not adopt a fully random conformation, which would
be characterized by a large negative []190–200 (11). It is possi-
ble that the flexibility of the polypeptide is restricted because of
the high Pro content of Apoptin (12.4%). The negative []200–210
could even suggest the presence of a poly-L-proline helix, al-
though an accompanying small positive []228 was absent (13).
Nevertheless, some of Apoptin’s Pro residues may adopt a
helix-like conformation. The broad negative []MRE of Apoptin
between 210 and 230 nm was reminiscent of CD spectra re-
ported for -turn- or -hairpin-containing peptides (14, 15).
However, the geometry of residues involved in -turns and
-hairpins can vary considerably, making their net contribution
to a CD spectrum poorly quantifiable. In general, the CD spec-
trum of refolded Apoptin-H6 was very similar to that of pro-
teins that are mostly unstructured (16–19).
The CD spectrum of MBP-Apoptin confirmed these observa-
tions, being not significantly different from that of MBP on its
own (Fig. 4B) (20, 21). First, this result shows that the Apoptin
moiety did not perturb the folding of MBP. Second, it demon-
strates that Apoptin did not contribute significantly to the
secondary structure content of the fusion protein. This is con-
sistent with the very low overall []MRE of refolded Apoptin-H6.
We conclude that Apoptin displays very little regular secondary
structure, but we cannot exclude that some residues adopt a
-strand or -turn conformation.
Intrinsic Fluorescence of Tyr95—Even though Apoptin did
not appear to adopt a well defined fold, the Apoptin polypeptide
might still display a certain degree of intra- or intermolecular
order within the multimeric complex. Because Apoptin-H6 does
not contain any Trp residues, the intrinsic fluorescence of its
single Tyr95 can act as a structural probe (22, 23). Tyr95 is
outside the multimerization domain defined by Apoptin’s N-
terminal residues. The excitation spectrum of Tyr95 in refolded
Apoptin-H6 was very similar to that of protonated L-Tyr(-OH),
with excitation maxima at 280 and 275 nm, respectively (Fig.
5A). However, the fluorescence emission spectrum of Apoptin’s
Tyr95 at pH 6.5 closely resembled that of deprotonated, free
tyrosine (L-Tyr(-O)) at pH 12 (Fig. 5B). This apparent discrep-
ancy can be explained by the effect that excitation has on the
pKa of the Tyr side chain; the pKa of Tyr(-OH) is near 10 in the
ground state but decreases to 4 upon excitation (24, 25).
Because the emission spectrum of refolded Apoptin-H6 was
almost entirely devoid of Tyr(-OH) fluorescence, an efficient
proton transfer to a nearby proton-accepting group (Glu, Asp,
or His) must have occurred upon excitation of Tyr95. This result
indicates that Tyr95 was hydrogen bonded. The fluorescence
yield of Tyr95 was increased by a factor of 4 to 5 relative to fully
deprotonated and solvent-exposed L-Tyr(-O) (at pH 12), which
indicates that Tyr95 was at least partially protected from the
solvent. The presence of an internal hydrogen bond involving
the side chain of Tyr95 suggests that at least one region of the
Apoptin polypeptide was able to adopt a more ordered
conformation.
Apoptin Did Not Bind Zn2 Despite a Putative Zn2-binding
Motif—Apoptin contains a potential metal-binding motif com-
prised of one His (His29) and three Cys residues (Cys30, Cys47,
and Cys49). Although this arrangement does not bear a clear
resemblance to any known metal-binding motifs, it is possible
that binding of a metal ion by Apoptin influences its secondary
structure content or multimerization behavior. The most obvi-
ous ligand for this motif would be Zn2. Including Zn2 in both
the expression medium and purification buffers did not affect
the expression level, solubility, or net yield of MBP-Apoptin
and Apoptin-H6. Furthermore, the CD spectra of MBP-Apoptin
and Apoptin-H6 were not significantly altered by the presence
of Zn2 added either after purification or during expression.
The presence of Zn2 affected neither efficiency nor specificity
of thrombin digestion of MBP-Apoptin nor the intrinsic fluo-
rescence of refolded Apoptin-H6. Finally, an assay based on the
strong increase in fluorescence upon Zn2 binding of the water-
soluble Zn2-selective chelating dye FluoZin-1 (26) indicated
that MBP-Apoptin expressed and purified in the presence of
FIG. 4. Circular dichroism spectra of MBP-Apoptin and re-
folded Apoptin-H6. Apoptin has a low secondary structure content but
may contain regions with -sheet or -turn structure. A, CD spectrum
of refolded Apoptin-H6, 40 M in 20 mM KPO4, pH 6.5, 1 mM MgSO4. B,
CD spectrum of MBP-Apoptin and MBP, both 6 M (monomer) in 10 mM
KPO4, pH 6.5, 0.1 mM EDTA.
FIG. 5. Intrinsic fluorescence emission and excitation spec-
trum of refolded Apoptin-H6. The single Tyr residue of Apoptin
(Tyr95) is involved in a stable hydrogen-bonding network. A, excitation
spectrum; B, emission spectrum.
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Zn2 contained less than 0.1 mole of Zn2 per mole of protein
(data not shown). We conclude that recombinant Apoptin does
not form a stable complex with Zn2.
MBP-Apoptin Expressed in Tumor Cells Exists
in an Aggregated State
Having established that recombinant Apoptin protein exists
exclusively as a remarkably homogenous and highly stable
aggregate in vitro, we evaluated the aggregation state of ec-
topically expressed MBP-Apoptin in human tumor cells (Saos-
2). As our data on recombinant MBP-Apoptin(66–121) and
MBP-Apoptin(1–69)-H6 suggested that Apoptin’s multimeriza-
tion domain resided in its N-terminal domain, we expressed
MBP-Apoptin(80–121) to compare the appearance of aggre-
gated full-length MBP-Apoptin with that of a truncated, puta-
tively non-aggregating MBP-Apoptin construct.
We inspected the morphological appearance of the two ex-
pressed construct in intact cells by immunofluorescence mi-
croscopy. Two days after transfection, a time point preceding
significant apoptosis induction in this cell type, full-length
MBP-Apoptin, was seen to form distinct globular particles in
the cytoplasm and nucleus of Saos-2 cells (Fig. 6A). Most strik-
ingly, a large proportion of the protein accumulated at the
nuclear rim, which may be caused by “congestion” of MBP-
Apoptin particles at or in the nuclear pores. In contrast, MBP-
Apoptin(80–121) had a much more diffuse appearance and was
predominantly located in the nucleus (Fig. 6A). We observed
essentially the same distribution in HeLa cells (data not
shown). These results suggest that full-length MBP-Apoptin
becomes aggregated in tumor cells, whereas MBP-Apoptin(80–
121) does not. Moreover, these results confirm that MBP itself
does not aggregate or contribute to the aggregation of its fusion
partner, which is in accordance with the properties of bacteri-
ally expressed MBP-Apoptin fusion proteins.
In parallel, we determined the aggregation state of both
protein constructs in cell extracts by centrifugation and found
that the bulk of the extracted full-length MBP-Apoptin could be
pelleted at 10,000  g, indicating that it is or is part of a very
dense aggregate (Fig. 6B). Moreover, most of the MBP-Apoptin
that remained in the supernatant could be pelleted at 30,000
g. Under the same conditions, MBP-Apoptin(80–121) was fully
soluble (Fig. 6A). Moreover, we verified that recombinant MBP-
Apoptin alone did not precipitate upon dilution in lysis buffer
(Fig. 6C). We assume that the trace amount of full-length
MBP-Apoptin remaining in the supernatant after centrifuga-
tion at 30,000 g corresponds to newly translated polypeptides
that were not yet fully aggregated or had been absorbed by
detergent micelles. Taken together with the immunofluores-
cence data, these results imply that aggregation of Apoptin
occurs in vivo and that the determinants responsible for aggre-
gation are located in the N-terminal part of the protein.
The Recombinant MBP-Apoptin Protein Complex Is Active
as a Multimeric Species
In a separate paper, we show that microinjected recombinant
MBP-Apoptin protein induces apoptosis in tumor Saos-2 cells,
but not in normal VH10 cells.3 This observation prompted us to
examine the role of aggregation of recombinant MBP-Apoptin
in apoptosis induction.
We established that recombinant Apoptin aggregates were
not dissolved by cellular factors in vitro under physiologically
relevant conditions; neither VH10 nor Saos-2 cell lysate af-
fected the size distribution of MBP-Apoptin aggregates in the
presence of ATP and Mg2, as tested by size exclusion chroma-
tography (data not shown). Furthermore, in both Saos-2 and
VH10 samples, the characteristic degradation pattern of MBP-
Apoptin remained unchanged upon incubation and fraction-
ation. A small amount of untagged Apoptin was present in the
starting material, and it remained associated with the intact
fusion protein without any changes in ratio (data not shown).
Next, to ensure that MBP-Apoptin aggregates did not dis-
solve upon microinjection into living cells, we cross-linked the
MBP-Apoptin aggregates by brief incubation with 0.05% glut-
araldehyde. The majority of these cross-links are expected to be
between the MBP moieties if the multimeric fusion protein, as
they contain most of the Lys residues. Cross-linked complexes
did not contain detectable amounts of smaller oligomers or
monomers (Fig. 7A). DLS analysis of cross-linked MBP-Apo-
ptin confirmed the presence of a single particle with an RH of
14.0  1.5 nm. First, this finding demonstrated that cross-
linking caused the MBP-Apoptin complex to become more com-
pact. Second, it showed that nearly all cross-linking occurred
within complexes, with a negligible number of linkages be-
tween different complexes being formed. To follow the fate of
MBP-Apoptin complexes upon microinjection, the fluorescent
label fluorescein-5-maleimide was attached to Apoptin’s single
solvent-exposed Cys residue prior to glutaraldehyde cross-link-
ing. When microinjected into the cytoplasm of Saos-2 cells, the
fluorescein-labeled, cross-linked MBP-Apoptin was imported
into the nucleus and induced the same level of apoptosis within
24 h as non-cross-linked MBP-Apoptin (Fig. 7, B and C). How-
ever, the efficiency of nuclear import of cross-linked MBP-
Apoptin appeared to be decreased in comparison to non-cross-
linked MBP-Apoptin (data not shown),3 which may indicate
that some of its nuclear localization signals are obscured as a
result of glutaraldehyde treatment. In VH10 cells, cross-linked
MBP-Apoptin remained in the cytoplasm and did not induce
apoptosis (Fig. 7, B and D). Clearly, covalent cross-linking did
not have any significant effect on the activity of microinjected
MBP-Apoptin, implying that in vivo dissociation of the recom-
binant Apoptin protein multimers is not required for tumor-
specific apoptosis induction.
DISCUSSION
Structure of the Apoptin Complex—We demonstrated with a
range of biophysical techniques that recombinant Apoptin pro-
tein forms multimeric globules of a distinct size that contain
about 30 monomers each. Our scanning force microscopy and
electron microscopy studies indicated that Apoptin multimers
have a roughly spherical shape. The presence of an 18-residue
FIG. 6. Ectopically expressed full-length MBP-Apoptin, but not
MBP-Apoptin(80–121), forms distinct globular aggregates in tu-
mor cells. Immunofluorescence and Western blot analysis of Saos-2
cells, transfected with full-length MBP-Apoptin and MBP-Apoptin(80–
121), are shown. A, immunofluorescence analysis of Saos-2, transfected
with full-length MBP-Apoptin and MBP-Apoptin(80–121). After fixa-
tion, the cells were stained with an anti-MBP antibody (MBP). Nu-
clear morphology is indicated by DAPI staining. Detection with anti-
Apoptin VP3-C produced similar results. B, Western blot analysis of
supernatant (S) and pellets (P) of lysed Saos-2 cells, expressing full-
length MBP-Apoptin and MBP-Apoptin(80–121). Cell extracts were
centrifuged at 10,000  g, yielding S10 and P10, and subsequently at
30,000  g, producing S30 and P30. Pos is purified, recombinant MBP-
Apoptin. Western blots were stained with VP3-C. C, Western blot
analysis of recombinant (Rec.) MBP-Apoptin centrifuged at a concen-
tration of 20 g/ml in lysis buffer alone.
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linker between MBP and Apoptin in the MBP-Apoptin fusion
protein increased its hydrodynamic radius, leading to an over-
estimation of its molecular mass. When MBP-Apoptin com-
plexes were cross-linked with glutaraldehyde, they became
more compact as judged by DLS, presumably because the MBP
moieties became firmly attached to each other and to the body
of the Apoptin core. On the basis of its hydrodynamic radius,
the theoretical molecular mass of the cross-linked MBP-Apo-
ptin complex is 1.6 MDa, corresponding to 30 monomeric sub-
units. This is fully consistent with the monomer content of
refolded Apoptin-H6 we observed.
CD spectroscopy indicated that Apoptin protein multimers
contain little if any secondary structure, which may reflect a
lack of internal ordering. This result raises the question of how
a seemingly disordered Apoptin polypeptide can assemble into
a biologically active and homogenous protein multimer. We
hypothesize that Apoptin multimers consist of only a limited
number of monomer conformations. Our experimental results
on recombinant Apoptin protein support such an idea. First, we
demonstrated that Apoptin’s Tyr95 forms a stable hydrogen
bond, which implies that there is at least some internal struc-
ture. Second, the CD spectrum of refolded Apoptin-H6 was
clearly different from that of a true random coil polypeptide,
indicating that its conformational freedom was restricted (11).
If Apoptin multimers present an at least partially ordered
surface, this characteristic would allow them to interact selec-
tively with cellular factors. Such an interaction could give rise
to a particular biological effect, namely the induction of apo-
ptosis in a tumor-specific manner. Furthermore, it could be
that small domains of the Apoptin multimer become ordered
once recognized by cellular factors. There are precedents for
such behavior; for example, high mobility group proteins spe-
cifically recognize DNA, yet in the absence of DNA do not adopt
a regular conformation (27).
According to secondary structure prediction, Apoptin might
fold as an anti-parallel -sheet between Glu32 and Leu46 with
Ala38 and Gly39 oriented in a -turn or -hairpin. The CD spec-
trum of refolded Apoptin-H6 is consistent with such a short
anti-parallel -sheet. In this motif (29HCREIRIGIAGITITLSL-
CGC49), small, mostly hydrophilic residues alternate with
seven Leu and Ile side chains. In addition, this motif is flanked
by a potential metal-binding site (His29, Cys30, Cys47, and
Cys49). However, we showed that this configuration of Cys and
His residues did not constitute a Zn2-binding site in recombi-
nant Apoptin. If this sequence indeed adopts a -hairpin-type
conformation, the large hydrophobic residues would all pro-
trude from one of the faces of the hairpin, whereas the hydro-
philic residues would protrude from the other. Such an am-
phipathic motif could well be essential for the multimerization
properties of Apoptin, perhaps by allowing the Leu and Ile
residues of neighboring Apoptin monomers to interlock. Our
observation that the presence of OG caused MBP-Apoptin to
precipitate does suggest that the multimerization of Apoptin is,
at least to an extent, based on hydrophobic interactions. It may
be that OG is more effective than CHAPSO and Triton in
disrupting Apoptin multimers because of its small size and
high micelle concentration (9 mM or 0.3%), allowing it to
penetrate the Apoptin core of MBP-Apoptin.
The Leu/Ile clustering of the potential amphipathic -hair-
pin is reminiscent of a Rev- or PKIlike nuclear export signal
(NES) (28). Although the NES sequences of PKI and of p53
have been reported to adopt an amphipathic -helical confor-
mation (29, 30), CD spectroscopy showed that refolded Apo-
ptin-H6 did not contain any -helical regions. If indeed the
isoleucines and leucines of the putative NES of Apoptin are
part of its multimerization motif, these residues would, be-
cause of their hydrophobic nature, be largely buried within the
multimer. Thus obscured, Apoptin’s putative NES would be
likely to have reduced activity.
Activity of the Apoptin Complex—We established that ectopi-
cally expressed, full-length MBP-Apoptin was aggregated in
live tumor cells, whereas truncated MBP-Apoptin(80–121) was
not. This difference in aggregation state was consistent with
our findings on recombinant MBP-Apoptin and truncated ver-
sions thereof. Moreover, the distribution of ectopically ex-
pressed MBP-Apoptin, including its accumulation at the nu-
clear envelope, was similar to that of the recombinant protein
following microinjection.3 Furthermore, the size of the aggre-
gates formed by full-length MBP-Apoptin in vivo was remark-
ably regular. Such homogeneity is strongly reminiscent of the
narrow size distribution of bacterially expressed MBP-Apoptin.
However, ectopically expressed MBP-Apoptin was contained in
an aggregate particle that was denser than the recombinant
Apoptin protein multimer. Therefore, it is likely that Apoptin
expressed in vivo forms a larger aggregate or co-aggregates
with other cellular proteins.
Our results suggest that aggregation of Apoptin in vivo does
not preclude induction of apoptosis, which would imply that
Apoptin does not have to be a properly folded molecule to be
active. Moreover, as most if not all ectopically expressed MBP-
Apoptin was found to be aggregated, it is very likely that this
aggregated state represents the physiological form of Apoptin
in tumor cells. Alternatively, it is possible that the protein
undergoes a transition between a folded and an unfolded state
in vivo upon binding to some cellular factor. We expect that an
inducible Apoptin expression system in human tumor cells will
FIG. 7. Cytoplasmic microinjection of fluorescein-labeled,
cross-linked MBP-Apoptin in Saos-2 and VH10 cells. Irreversible
cross-linking of the MBP-Apoptin complex does not affect its nuclear
localization or its apoptosis-inducing ability. The Apoptin moiety of
MBP-Apoptin was labeled with fluorescein-5-maleimide, and the mul-
timers were cross-linked with 0.05% glutaraldehyde. The incorporation
level of fluorescein was near 100%. The fluorescein- and glutaralde-
hyde-modified MBP-Apoptin was microinjected in Saos-2 and VH10
cells. 100 cells per dish were injected with modified MBP-Apoptin (3
mg/ml, in PBS) and fixed at 2 and 24 h after injection. Injected cells
were identifiable by co-injected Lys-fixable rhodamine-dextran. A, 7.5%
SDS-PAGE analysis of fluorescein-labeled, cross-linked MBP-Apoptin.
1, non-cross-linked MBP-Apoptin; 2, cross-linked MBP-Apoptin. B, level
of apoptosis induction, as determined by DAPI staining. C, microin-
jected Saos-2 cells at 2- and 24-h time points, combined with DAPI
staining. DF, direct fluorescence of fluorescein-labeled MBP-Apoptin.
D, microinjected VH10 cells at 2- and 24-h time points, combined with
DAPI staining.
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allow us to evaluate the molecular mass distribution of ectopi-
cally expressed Apoptin in more detail.
Based on the findings reported here, we hypothesize that the
multimeric state is the functional form of recombinant MBP-
Apoptin, which we propose to be analogous to the aggregated
state of ectopically expressed MBP-Apoptin. First, cell lysates
could not bring about the efficient dissolution of the Apoptin
multimers into monomers or smaller oligomers. Second, chem-
ical cross-linking of MBP-Apoptin did not significantly affect its
subcellular localization and apoptosis-inducing ability in hu-
man tumor cells. Moreover, cross-linked Apoptin protein mul-
timers did not kill normal cells. Taken together, these results
clearly demonstrate that Apoptin does not have to adopt a
monomeric form to be active as a tumor-specific apoptosis-
inducer. Nevertheless, these results do not formally rule out
the possibility that Apoptin might exist as a monomer in vivo.
However, it should be noted that both MBP-Apoptin and Apo-
ptin-H6 multimers were found to be remarkably stable. They
could not be dissolved under native conditions in vitro, suggest-
ing that no significant amounts of monomeric Apoptin were
ever released. Even under denaturing conditions (8 M urea or 6
M guanidinium hydrochloride), the interactions between indi-
vidual Apoptin proteins were only partially abolished (data not
shown). Clearly, the driving force behind multimer formation is
dominant both in the intracellular environment of E. coli and
while Apoptin-H6 was tethered to Ni
2-chelating resin under
refolding conditions, which suggests that multimerization is
probably the fate of a significant fraction of in vivo expressed
Apoptin, as well. In all, we conclude that aggregated, or mul-
timeric, recombinant Apoptin protein contains the essential
features that allow Apoptin, expressed in vivo, to induce apo-
ptosis in a tumor-specific manner. Moreover, we conclude that
the lack of secondary structure in recombinant Apoptin protein
is likely to reflect, at least to some extent, the intrinsically
disordered nature of Apoptin.
There are many examples of proteins that can undergo con-
trolled denaturation/aggregation or polymerization in vitro
(31–33). In general, controlled aggregation occurs under condi-
tions that stabilize a particular folding intermediate. The dis-
ruption of a folding pathway in vivo that leads to the accumu-
lation of such intermediates in intracellular aggregates is
linked to several pathological processes. Hence, evolution of
protein secondary and tertiary structure is thought to be
aimed, at least in part, on bypassing such kinetic folding
“sinks” of partially folded polypeptides (34). A well documented
example of a pathogenic, aggregation-prone protein is hunting-
tin, the pathogenic effect of which is characterized by the for-
mation of intranuclear aggregates of N-terminal huntingtin
fragments, an event that is directly linked to apoptosis induc-
tion (35). An example where protein aggregation seems to
represent “gain-of-function” is the human milk protein -lac-
talbumin, which forms partially unfolded oligomers that are
imported into the nucleus of tumor and differentiating cells,
whereas the monomeric form is not. Nuclear import of oligo-
meric -lactalbumin was accompanied by induction of apopto-
sis (36, 37). It has been suggested that the presence of globular
aggregates of misfolded protein in the cell may lead to cell
death if these aggregates are efficient nucleation sites for fi-
brous amyloid formation (33). However, the globular aggre-
gates of recombinant Apoptin did not form recognizable fibrous
amyloid deposits when microinjected into live cells,3 and such
amyloid formation by Apoptin was also not observed in vitro in
the current study. Therefore, the mechanism of apoptosis in-
duction by Apoptin is clearly different. Moreover, apoptosis
induction by recombinant Apoptin multimers is not a general
cytotoxic effect, as Apoptin does not appear to elicit any harm-
ful effects when introduced into several different normal pri-
mary human cells.3 Apoptin will exert its pro-apoptotic func-
tion only when a cell has entered the pathway that leads to a
transformed state (38). In that respect, Apoptin clearly differs
from proteins that give rise to aggregation-linked diseases (39).
Apoptin is a viral protein encoded by chicken anemia virus.
The virus has a minimal single-stranded DNA genome, and
Apoptin’s gene fully overlaps with that of the VP2 protein,
albeit with a shift in frame (40). One possible function of
Apoptin in the replication cycle of CAV is to induce apoptosis of
infected chicken thymocytes to release them from the host cell
once the viral particles have matured. Transmission of CAV
may be enhanced when the virus is encased in or associated
with apoptotic bodies, analogous to adenoviral vectors (41). In
such a process, the potential co-transmission of Apoptin glob-
ules, together with infectious viral particles, may also have a
biological function. In this respect it is striking that Apoptin
forms a globular particle roughly the size of a virus, so it may
have an evolutionary relationship with a viral coat protein. The
requirement of a compact genome in CAV has impelled the
Apoptin gene to fully overlap with that of VP2 in the viral
genome. The obvious price of this compactness is that the
sequences of both genes are more strongly constrained. How-
ever, if a protein’s function requires it merely to aggregate,
rather than to adopt a well defined quaternary conformation,
the constraints on its sequence will be less stringent.
It is well possible that Apoptin’s original function has de-
manded its multimerization, which it may have achieved
through random aggregation as outlined above, rather than
through the formation of a specific quaternary structure. If so,
Apoptin provides an example of a novel route for the evolution
of protein function. There are several possible explanations
why the multimerization of Apoptin may be essential for its
biological function; e.g. aggregation may stabilize Apoptin,
which in its ill-defined monomeric form may be readily degrad-
able, or the formation of globular multimers may result in
cooperative binding of Apoptin moieties to certain large ligands
or molecular complexes (DNA, RNA, chromatin, nuclear pores,
etc.). Obviously these possibilities do not exclude one another,
underscoring the likeliness that in the case of Apoptin the
classical structure/function paradigm translates as an aggre-
gation/function paradigm.
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